{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:17:21Z","timestamp":1789345041377,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We sought to investigate the molecular mechanism underlying transformation of chronic lymphocytic leukemia (CLL) to histiocytic sarcoma (HS) with indeterminate dendritic cell (IDC) features.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Extensive NGS-based genomic profiling was performed on samples of a patient who had CLL, secondary HS with IDC features, and CMML. Clonotypic evaluation of VDJ rearrangement status was performed to confirm clonal relatedness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HS is a rare proliferation of malignant tissue histiocytes that is usually primary, although secondary HS exists and often demonstrates mutations in the Ras\/Raf\/MAPK or PI3K\/AKT\/mTOR pathways, but HS with indeterminate dendritic cell (IDC) features has not been previously reported. A 77-year-old man with chronic lymphocytic leukemia (CLL) presented with an oropharyngeal mass. Biopsy specimen showed large atypical histiocytic cells with oval-to-irregular indented nuclei. They were positive for CD33, CD4, CD68 (subset, weak), CD163 (subset, weak), BCL6, S100 (subset), CD1a, cyclin D1 (subset), and lysozyme (weak) but negative for Langerin, BRAF V600E, CD21, CD23, CD35, CD123, TCF4, TCL1, MPO, CD20, CD79a, CD10, MUM1, and BCL2. The patient was diagnosed with secondary HS with IDC features as well as chronic myelomonocytic leukemia (CMML) in the bone marrow. Careful genomic dissection of all 3 types of malignant cells showed that SF3B1 p.E622D was present in both CLL and HS but not CMML. In addition, the HS acquired KRAS p.G13D, which we hypothesize drove the transdifferentiation of CLL to HS. Moreover, next-generation sequencing (NGS) clonotypic evaluation of variable-diversity-joining (VDJ) rearrangements in both the HS and CLL established relatedness but not the CMML.Conclusion: This is the first report of secondary HS with IDC features arising from CLL. We establish by both IGH NGS analysis and mutational profiling that the CLL and HS are clonally-related and posit that acquisition of KRAS p.G13D drove transdifferentiation. This has therapeutic implications for targeting the RAS-BRAF-MAPK-ERK pathway.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf041","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:57:53Z","timestamp":1748267873000},"page":"157-162","source":"Crossref","is-referenced-by-count":2,"title":["<i>KRAS<\/i> may facilitate transformation of chronic lymphocytic leukemia to histiocytic sarcoma with indeterminate dendritic cell features"],"prefix":"10.1093","volume":"164","author":[{"given":"Farhan","family":"Hassan","sequence":"first","affiliation":[{"name":"University of Missouri\u2013Kansas City (UMKC) College of Medicine , Kansas City, MO ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich Werner","family":"Idiaquez","sequence":"additional","affiliation":[{"name":"Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagehan","family":"Pakasticali","sequence":"additional","affiliation":[{"name":"Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hyjek","sequence":"additional","affiliation":[{"name":"Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-0489","authenticated-orcid":false,"given":"Mohammad","family":"Hussaini","sequence":"additional","affiliation":[{"name":"Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2025082604520232700_CIT0001","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5581\/1516-8484.20110038","article-title":"Histiocytic sarcoma","volume":"33","author":"Machado","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"2025082604520232700_CIT0002","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/diagnostics11020310","article-title":"Histiocytic sarcoma: challenging course, dismal outcome","volume":"11","author":"Andersen","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2025082604520232700_CIT0003","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ejh.12755","article-title":"Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment","volume":"97","author":"Ansari","year":"2016","journal-title":"Eur J Haematol."},{"key":"2025082604520232700_CIT0004","doi-asserted-by":"publisher","first-page":"650","DOI":"10.5858\/arpa.2018-0349-RS","article-title":"Histiocytic sarcoma","volume":"144","author":"Hung","year":"2020","journal-title":"Arch Pathol Lab Med."},{"key":"2025082604520232700_CIT0005","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","article-title":"The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy","volume":"34","author":"Egan","year":"2021","journal-title":"Mod Pathol."},{"key":"2025082604520232700_CIT0006","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/j.clml.2018.07.286","article-title":"Clinicopathologic features and clinical outcome differences in de novo versus secondary histiocytic sarcomas: a multi-institutional experience and review of the literature","volume":"18","author":"Broadwater","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082604520232700_CIT0007","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ajcp\/aqad022","article-title":"B-cell lineage neoplasms transdifferentiating into histiocytic\/dendritic cell neoplasms: diversity, differentiation lineage, genomic alterations, and therapy: report from the 2021 SH\/EAHP Workshop","volume":"159","author":"Xiao","year":"2023","journal-title":"Am J Clin Pathol."},{"key":"2025082604520232700_CIT0008","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/PAT.0b013e32834685b7","article-title":"Indeterminate dendritic cell tumour presenting in a patient with follicular lymphoma","volume":"43","author":"Bettington","year":"2011","journal-title":"Pathology (Phila)."},{"key":"2025082604520232700_CIT0009","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"2025082604520232700_CIT0010","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/DAD.0000000000001191","article-title":"Indeterminate dendritic cell tumor: a report of two new cases lacking the ETV3-NCOA2 translocation and a literature review","volume":"40","author":"Davick","year":"2018","journal-title":"Am J Dermatopathol."},{"key":"2025082604520232700_CIT0011","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/modpathol.2011.102","article-title":"Clonally related histiocytic\/dendritic cell sarcoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: a study of seven cases","volume":"24","author":"Shao","year":"2011","journal-title":"Mod Pathol."},{"key":"2025082604520232700_CIT0012","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2017-10-812495","article-title":"Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes","volume":"131","author":"Kommalapati","year":"2018","journal-title":"Blood."},{"key":"2025082604520232700_CIT0013","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14740\/jh1310","article-title":"Transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma to histiocytic\/dendritic cell sarcoma","volume":"13","author":"Cai","year":"2024","journal-title":"J Hematol"},{"key":"2025082604520232700_CIT0014","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarfo","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"2025082604520232700_CIT0015","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","article-title":"Targeting oncogenic Ras signaling in hematologic malignancies","volume":"120","author":"Ward","year":"2012","journal-title":"Blood."},{"key":"2025082604520232700_CIT0016","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/cancers14030666","article-title":"KRAS and RAS-MAPK pathway deregulation in mature B cell lymphoproliferative disorders","volume":"14","author":"Vendramini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025082604520232700_CIT0017","doi-asserted-by":"publisher","first-page":"e25814","DOI":"10.7759\/cureus.25814","article-title":"Histiocytic sarcoma: clinical features and outcomes of patients treated at a tertiary cancer care center","volume":"14","author":"Susan Joy Philip","year":"2022","journal-title":"Cureus"},{"key":"2025082604520232700_CIT0018","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12185-014-1630-y","article-title":"Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation","volume":"100","author":"Tsujimura","year":"2014","journal-title":"Int J Hematol."},{"key":"2025082604520232700_CIT0019","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.2169\/internalmedicine.6948-20","article-title":"Successful treatment of incidental histiocytic sarcoma concomitant with laryngeal carcinoma","volume":"60","author":"Oka","year":"2021","journal-title":"Intern Med."},{"key":"2025082604520232700_CIT0020","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3324\/haematol.2018.196931","article-title":"Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia","volume":"104","author":"Gimenez","year":"2019","journal-title":"Haematologica."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/2\/157\/63360613\/aqaf041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/2\/157\/63360613\/aqaf041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T08:52:10Z","timestamp":1756198330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/164\/2\/157\/8150905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,26]]},"published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf041","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,26]]}}}